Brief: Bristol Myers Squibb And 2seventy bio Share Update

2Seventy Bio

05/02/2024 12:56

Feb 5 (Reuters) - Bristol-Myers Squibb Co  BMY.N :
    * BRISTOL MYERS SQUIBB AND 2SEVENTY BIO SHARE UPDATE ON U.S.
FDA
ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING FOR ABECMA IN
TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA BASED ON KARMMA-3 STUDY
    * BRISTOL-MYERS SQUIBB CO - COMPANIES ANTICIPATE THAT ODAC
WILL
REVIEW DATA RELATED TO SECONDARY ENDPOINT OF OVERALL SURVIVAL
(OS) FROM STUDY
    * BRISTOL-MYERS SQUIBB CO: FDA WILL CONVENE A VIRTUAL
MEETING OF
ODAC ON MARCH 15 TO REVIEW DATA SUPPORTING SBLA FOR ABECMA

Source text for Eikon:  ID:nBw3WLThFa 
Further company coverage:  BMY.N